Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women With Low Bone Density.

The article discusses a study which examined the role of the cathepsin K inhibitor odanacatib in osteoporosis. The clinical trial involved postmenopausal women with low bone mineral density (BMD). The clinical trial found that two years of weekly treatment with odanacatib was generally well tolerated by the patients. The drug also increased lumbar spine and total hip BMD in the patients.